Figure 3.

Novel pharmacologic compounds targeting metabolic and inflammatory pathways in NAFLD. During development and progression of NAFLD, multiple signalling pathways are dysregulated. Preclinical and clinical studies identified many potential drug targets for the treatment of nonalcoholic steatohepatitis and fibrosis. Targeting metabolic and inflammatory mechanisms of action (blue) represent promising strategies, which led to the development of various therapeutic compounds (orange), which are currently under clinical investigation. SCD1, stearoyl-CoA desaturase 1; PPAR, peroxisome proliferator-activated receptor; FGF, fibroblast growth factor; FXR, Farnesoid X receptor; FFA, free fatty acids.